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Abstract 
Introduction Relationships between faecal haemoglobin concentrations (f-
Hb) below the cut-off used in colorectal cancer (CRC) screening and longer-
term outcomes are not well established. 
Objectives To examine associations between f-Hb reported as negative and 
outcomes in the next screening round. 
Setting Scottish Bowel Screening Programme. 
Methods f-Hb and diagnostic outcomes were investigated for participants with 
a negative result, f-Hb cut-off < 80.0 µg Hb/g faeces, but then positive within 
the next two years. 
Results Of 37,780 with a negative result, at the next screening round 556 
(1.5%) had positive and 30,293 (80.2%) negative results. Initial median f-Hb 
(2.1 µg Hb/g faeces, IQR: 0.0 - 13.2) was higher in those with a subsequently 
positive result than those who had a negative result at the next round (0.0 µg 
Hb/g faeces, IQR: 0.0 - 1.4; p < 0.0001). Using f-Hb 0.0 - 19.9 µg Hb/g faeces 
as reference, logistic regression analysis showed high adjusted OR for 
advanced neoplasia (AN: CRC or higher-risk adenoma) detection at the next 
round of 14.3 (95% CI: 8.9 - 23.1) in those with initial f-Hb 20.0 - 39.9 µg Hb/g 
faeces and 38.0 (95% CI: 20.2 – 71.2) with 60.0 - 79.9 µg Hb/g faeces. 
Conclusions A higher proportion of participants with f-Hb of ≥20 µg Hb/g 
faeces had AN detected at the next round, compared to those with lower f-Hb.  
Although most relevant when using high f-Hb cut-offs, studies of f-Hb and 
outcomes over screening rounds may provide strategies to direct available 
colonoscopy towards those at highest risk.  
Introduction 
 
Participants in colorectal cancer (CRC) screening programmes with faecal 
haemoglobin concentrations (f-Hb) that are below the selected cut-off for 
positivity and referral for follow-up colonoscopy, as determined by a 
quantitative faecal immunochemical test (FIT) for haemoglobin (Hb), are more 
likely to be diagnosed with an interval cancer (IC) than those with 
undetectable f-Hb.1  Rarely documented, however, has been the relationship 
between a detectable f-Hb below the programme selected cut-off and 
diagnostic outcome in the longer term. Such knowledge could assist in 
determining the role of f-Hb as a predictor of the future risk of advanced 
neoplasia (AN), defined as CRC plus higher-risk adenoma (HRA).   
Only two relevant studies have been performed previously. Firstly, in a 
longitudinal follow-up of CRC screening participants in Taiwan,2 a cohort of 
44,324 participants, aged 40 - 69 years, with f-Hb below the cut-off applied of 
>20.0 µg Hb/g faeces were followed for a median of 4.39 years.  The 
incidence of AN rose from 1.75/1000 person-years for those with f-Hb of 0.2 – 
3.9 µg Hb/g faeces to 7.08/1000 in those with f-Hb of 16.0 – 19.9 µg Hb/g 
faeces. Moreover, relative to those with f-Hb of 0.2 – 3.9 µg Hb/g faeces, 
adjusted hazard ratios (HR) for AN were calculated as 3.41 for those with f-Hb 
in the category lower than but closest to the cut-off f-Hb used (16.0 – 19.9 µg 
Hb/g faeces). Secondly, a recent study documents results of regression 
modelling to further establish the value of f-Hb as a predictor for colorectal 
neoplasia: 3 54,921 participants invited between 2001 and 2007 were followed 
up in the annual FIT-based CRC screening programme in Taiwan to identify 
those diagnosed with IC, screen-detected CRC and adenoma.  A trend of 
increasing HR with increasing baseline f-Hb was demonstrated for colorectal 
neoplasia, including for those with f-Hb above the traditionally used cut-off of 
> 20 µg Hb/g faeces. 
Thus, the available limited evidence indicates that the higher the baseline f-
Hb, the greater the likelihood of a future finding of AN. If verified, this could 
have implications for the design and execution of CRC screening 
programmes; for example, those with a negative screening test result who are 
at high risk of having AN by virtue of a detectable f-Hb despite being lower 
than the cut-off f-Hb applied, could be prioritised for future repeat screening at 
a shorter interval than the current usual annual or biennial invitation. 
Conversely, those with undetectable f-Hb, and therefore deemed very unlikely 
to have a future finding of AN, could perhaps require less frequent invitations 
to screening. Such a strategy could be an important consideration in countries 
such as Scotland where, in view of demands on the colonoscopy resource, 
adoption of a cut-off f-Hb of  > 80.0 µg Hb/g faeces (equivalent to > 400 ng 
Hb/ml buffer) for the planned FIT-based programme is likely, given that this 
was used in the pilot evaluation required to inform future adoption of FIT as a 
first-line test.4 This f-Hb cut-off was selected in order to achieve approximately 
2% positivity, to mimic the current screening algorithm based on a two-tier 
reflex guaiac faecal occult blood test (gFOBT)/qualitative FIT strategy.4  Since 
it is known that IC are common at this f-Hb cut-off,1 it is reasonable to 
postulate is that a proportion of participants with f-Hb < 80.0 µg Hb/g faeces 
will have AN detected at the next screening round.  Our aim therefore, was to 
investigate the relationship between f-Hb reported as a negative screening 
test result in our FIT evaluation and diagnostic outcomes identified over the 
two year period of the next screening round to test the hypothesis that those 
with f-Hb lower than but closer to the cut-off applied are more likely to be 
subsequently diagnosed with AN. 
 
Materials and Methods 
Outside the setting of the FIT evaluation, the Scottish Bowel Screening 
Programme (SBoSP) uses a two-tier reflex gFOBT/FIT screening algorithm, 
which has been described in detail previously.4 The pilot evaluation of using 
FIT as a first-line screening test in Scotland has also been described in detail 
previously:5 all participants with f-Hb ≥ 80.0 µg Hb/g faeces were reported as 
positive and offered colonoscopy.  
 
Following completion of the FIT evaluation, the SBoSP returned the two NHS 
Boards to the two-tier reflex gFOBT/FIT screening algorithm. The screening 
test results for all those eligible to take part in the two years of the next 
screening round after the FIT evaluation (13 January 2011 to 12 January 
2013) and resident in either NHS Tayside or NHS Ayrshire & Arran were 
examined. The f-Hb from the previous FIT-based pilot evaluation round for 
those with a positive gFOBT/FIT screening test result was retrieved from the 
Scottish Bowel Screening IT System (BoSS). Data for colonoscopy outcomes 
and any subsequent pathology for those with a positive test result were 
downloaded from the appropriate clinical IT systems in NHS Tayside and 
NHS Ayrshire & Arran. Data on colonoscopy findings, including number, size, 
Dukes’ stage, and localisation of CRC and adenomas were collected. As in 
the SBoSP, HRA were defined as those greater than 10 mm in diameter or 
when there were three or more adenoma present:6 AN was defined as CRC 
and HRA. 
MedCalc (MedCalc Software, Mariakerke, Belgium) statistical software was 
used for all calculations. The Mann-Whitney U test was used for comparison 
of median f-Hb between classes. Probability of p < 0.05 was considered 
significant. Logistic regression analysis was performed to calculate odds 
ratios (OR) for diagnosis of AN at the next screening round amongst those in 
different f-Hb classes and different demographic groups, both adjusted and 




The majority of participants (37,780) in the FIT pilot evaluation had an initial 
negative test result.5 Of those, 92.7% were eligible for an invitation to further 
screening with the gFOBT/FIT algorithm: the majority of those not invited were 
above the age limit applied in the SBoSP (75 years), with others having died 
or being no longer resident in Scotland. In total, 30,849 participants 
participated in the FIT evaluation and the subsequent screening round with 
gFOBT/FIT. Table 1 details the outcomes of all participants who had f-Hb < 80 
µg Hb/g faeces, the cut-off used in the FIT evaluation, by age and gender. 
 Table 1. Number of participants with a negative FIT screening test result 
and their screening test results in two years in the next gFOBT/FIT 
screening round.  
   All Men Women 
   n % n % n % 
Total with negative FIT screening 
test result < 80.0 µg Hb/g faeces 37,780   17,525   20,255   
       
Test result in next gFOBT/FIT 
round:       
 Positive 556 1.5 339 1.9 217 1.1 
 Negative 30,293 80.2 13,910 79.4 16,383 80.9 
 Non-responder 4,165 11.0 1,976 11.3 2,189 10.8 
 Excluded 2,766 7.3 1,300 7.4 1,466 7.2 
 
556 (1.5%) participants had a positive test result in the subsequent screening 
round and 30,293 (80.2%) had a negative test result. The initial median f-Hb 
was statistically significantly higher in those who then had a positive test result 
in the next round than those who remained negative (2.1 µg Hb/g faeces, IQR 
0.0 - 13.2 v 0.0 µg Hb/g faeces, IQR 0.0 - 1.4; p < 0.0001). 
Table 2 shows the diagnostic outcomes, with median f-Hb, of participants who 
had a positive test result in the next screening round.  The differences in 
median f-Hb between men and women were only statistically significant in 
those diagnosed at colonoscopy with either non-neoplastic pathology or 
normal findings (both p < 0.05).
Table 2. Diagnostic outcomes and median faecal haemoglobin concentrations (f-Hb) at the initial FIT screening round in 
participants then having a positive screening test result at the next gFOBT/FIT screening round.  
 All  Men  Women 
  n % 
initial median 
f-Hb 










(µg Hb/g faeces) IQR 
Total positive 556  2.1 0.0 - 13.0  339  1.6 1.2 - 3.0  217  2.4 0 - 12.9 
Colorectal cancer (CRC) 26 4.7 16.7 1.2 - 31.6  19 5.6 21.0 0.5 - 36.3  7 3.2 10.2 2.5 - 24.0 
Higher risk adenoma (HRA) 85 15.3 13.6 1.2 - 38.5  63 18.6 9.6 0.9 - 38.8  22 10.1 16.6 1.8 - 35.2 
Advanced neoplasia (AN: 
CRC and HRA) 111 20.0 13.6 1.2 - 37.6 
 
82 24.2 14.7 0.8 - 38.8 
 
29 13.4 13.6 1.8 - 35.2 
Low risk adenoma 65 11.7 1.7 0.0 - 8.5  42 12.4 1.6 0.0 - 10.9  23 10.6 1.8 0.0 - 7.0 
Non-neoplastic pathology 131 23.6 1.6 0.0 - 7.4  72 21.2 0.7 0.0 - 5.8  59 27.2 3.4 0.1 -15.1 
Normal findings  169 30.4 1.4 0.0 - 6.2  93 27.4 0.3 0.0 - 5.6  76 35.0 2.0 0.0 - 7.3 
Footnote: IQR is the interquartile range (difference between the upper quartile and the lower quartile); non-neoplastic pathology comprises 
conditions including diverticular disease, haemorrhoids and inflammatory bowel disease and haemorrhoids.
A numerical f-Hb result was available for 30,823 of the 30,849 participants in 
both screening rounds.  The majority of these (96.6%) had f-Hb in the FIT 
round that was in the lowest class of 0.0 - 19.9 µg Hb/g faeces.  87.4% of 
participants with a positive gFOBT/FIT result who did not have AN detected 
were in this low f-Hb class, compared to only 56.8% of those with AN.  The 
proportions of participants with different diagnostic outcomes according to 
which class of f-Hb they fell into at the initial screening round with FIT are 
shown in Table 3. A lower proportion of participants with previously low f-Hb 
had AN detected than less severe outcomes, but this trend reversed with 
rising f-Hb: this is demonstrated in Figure 1. Since a commonly used f-Hb cut-
off for screening programmes outside Scotland is > 20 µg Hb/g faeces, Table 
4 shows further analysis of the class with a f-Hb below this concentration, 
dissected into two f-Hb classes; those with undetectable f-Hb at the initial FIT 
screening round and those with f-Hb 1.0 - 19.9 µg Hb/g faeces. 
 
 
Table 3. Outcomes of participants in both screening rounds according 




Faecal haemoglobin concentration class 
in the initial FIT screening round 
(µg Hb/g faeces) 
  0.0 - 19.9 20.0 - 39.9 40.0 - 59.9 60.0 - 79.9 
Outcome in next 
FOBT/FIT screening round n % n % n % n % 
Negative screening test result 29,049 96.6% 661 2.2% 227 0.8% 125 0.4% 
Positive screening test result 449 80.8% 59 10.6% 26 4.7% 22 4.0% 
          
Follow-up complete 383  52  22  20  
Footnote: Non-neoplastic pathology comprises conditions including diverticular 
disease, haemorrhoids and inflammatory bowel disease and haemorrhoids. 
 
Figure 1. Percentages of FIT positive screening participants completing 
follow-up who had advanced neoplasia (AN) or less severe outcomes in 
the next gFOBT/FIT screening round, according to faecal haemoglobin 




 Colorectal cancer (CRC) 14 3.7% 7 13.5% 1 4.5% 4 20.0% 
 Higher-risk adenoma (HRA) 49 12.8% 17 32.7% 10 45.5% 9 45.0% 
 Advanced neoplasia (AN: 
CRC and HRA) 63 16.4% 24 46.2% 11 50.0% 13 65.0% 
 Low-risk adenoma  58 15.1% 8 15.4% 2 9.1% 0 0.0% 
 Non-neoplastic pathology 115 30.0% 6 11.5% 7 31.8% 3 15.0% 
 No pathology detected 147 38.4% 14 26.9% 2 9.1% 4 20.0% 
Footnote: Non-neoplastic pathology comprises conditions including diverticular 
disease, haemorrhoids and inflammatory bowel disease and haemorrhoids. 
 
Table 4. Outcomes of participants of both screening rounds with faecal 
haemoglobin concentration < 20 µg Hb/g faeces at the initial FIT 
screening round, dissected into two classes. 
Footnote: Non-neoplastic pathology comprises conditions including diverticular 
disease, haemorrhoids and inflammatory bowel disease and haemorrhoids. 
 
As shown in Table 5, logistic regression analysis showed very high age and 
gender adjusted OR for AN even in those with f-Hb 20.0 - 39.9 µg Hb/g 
faeces, using those with f-Hb 0.0 - 19.9 µg Hb/g faeces as the reference 
group (adjusted OR = 14.3, 95% CI 8.9 - 23.1).  Almost one-tenth of all 
participants who had f-Hb within the highest f-Hb class examined, 60.0 - 79.9 
µg Hb/g faeces, and participated in the subsequent round, had AN detected at 
 
 
Faecal haemoglobin concentration class 
in the initial FIT screening round 
(µg Hb/g faeces) 
  Undetectable 1.0 - 19.9 
Outcome in subsequent 
screening round n % n % 
Negative screening test result 16,621 56.8 12,633 43.2 
Positive screening test result 181 40.3 268 59.7 
      
Follow-up complete 151  232  
 Colorectal cancer (CRC) 5 3.3 9 3.8 
 Higher-risk adenoma (HRA) 14 9.3 35 15.1 
 Advanced neoplasia (AN: CRC and HRA) 19 12.6 44 19.0 
 Lower-risk adenoma (LRA) 24 15.9 34 14.7 
 Non-neoplastic pathology 43 28.5 72 31.0 
 No pathology detected 65 43.0 82 35.3 
the follow-up investigations of a positive test result.  AN was over 40-times 
more prevalent in this class than those with f-Hb previously 0.0 - 19.9 µg/g 
faeces, of whom 0.21% had AN.  The adjusted odds ratio for AN in the 
highest f-Hb class was calculated to be 38.0 (95% CI 20.2 - 71.2). 
 
Table 5. Odds ratios (both unadjusted and adjusted for age and gender) 
for advanced neoplasia (AN) found at the next gFOBT/FIT round after a 
positive screening test result, according to faecal haemoglobin 
concentration (f-Hb) class in the previous FIT screening round. 
f-Hb class 
 (µg Hb/g faeces) 




(95% CI) (95% CI) 
0.0 - 19.9 0.2% 1.0 1.0 
20.0 - 39.9 3.4% 16.2 (10.1 - 26.2) 14.3 (8.9 - 23.1) 
40.0 - 59.9 4.4% 21.5 (11.2 - 41.4) 17.7 (9.2 - 34.2) 
60.0 - 79.9 9.0% 45.9 (24.7 - 85.4) 38.0 (20.2 - 71.2) 




The finding that a higher proportion of participants with a previous f-Hb lower 
than, but approaching, the cut-off used in our FIT pilot evaluation had AN 
detected at the next round, compared to those with low f-Hb, provides further 
evidence that f-Hb is a strong predictor of future risk.  
Positivity in those participants who, in the previous round, had f-Hb below the 
cut-off applied of > 80.0 µg Hb/g faeces was 1.5%.  This was lower than the 
overall positivity seen in the FIT pilot evaluation done in Scotland7 and also 
with the current gFOBT/FIT algorithm at ca. 2%.4  This suggests that those 
who have previously had a negative screening test result, even with a 
relatively high cut-off f-Hb, are less likely to have a positive test result in the 
subsequent screening round compared with the overall population invited for 
screening, which would include first-time participants as well as participants 
who have previously had a positive test result. 
Our findings further support the concept of f-Hb being a valuable predictor of 
risk of AN since f-Hb was statistically significantly elevated, not only in those 
who would go on to have a positive test result in the next round compared to 
those who again had a negative result, but also in those who had AN detected 
at follow-up investigations compared with those with no pathology (both p < 
0.0001). Furthermore, one in five participants who had f-Hb in the f-Hb range 
nearest to the cut-off f-Hb applied and were then positive in the next 
screening round, were diagnosed with CRC. This compares with one in 27 
participants in the lowest f-Hb class examined: thus, those with elevated f-Hb 
who go on to have a positive screening test result in the next round are over 
five times more likely to have CRC detected. When also taking into account 
detection of HRA, 65% of those participants with a positive screening test 
result who previously had f-Hb in the highest f-Hb class examined had any AN 
diagnosed, compared to just 16.4% in the lowest. Moreover, a trend exists of 
a higher proportion of AN found in participants from each of the four classes 
of increasing f-Hb.  From these data, the odds of having AN detected 
following a positive screening result are even in those with previous f-Hb 
between 40.0 and 59.9 µg/g faeces. After this point, it is more likely than not 
that AN will be present at follow-up investigations in those with a positive 
screening test result in the next round.  Almost one-tenth of all participants 
with f-Hb approaching the cut-off f-Hb applied went on to have AN detected, 
representing a 40-fold increase in the risk as compared to those in the lowest 
f-Hb class. This finding is important when considering f-Hb as a predictor of 
future risk of AN at the time of a negative screening test result. Not only is 
strong evidence provided for the value of f-Hb as a risk factor for AN being 
detected at follow-up investigations of participants going on to have a positive 
test result, but also for predicting future positivity and the subsequent 
detection of AN. In addition, since it has been suggested that f-Hb is a 
predictor, not only of CRC mortality, but also all-cause death,8 there may be 
other benefits in the more general application of f-Hb as a predictor of ill 
health. 
If screening programmes collect data such as this, irrespective of the faecal 
test used, then the effect of cut-off f-Hb on yield of AN can be determined 
using a graph such as shown in our Figure 1. The f-Hb where the percentage 
of participants with positive screening test results completing follow-up who 
had advanced neoplasia (AN) crosses that of those less severe outcomes can 
give an indication of the cut-off f-Hb associated with the greatest benefit in 
terms of yield of advanced neoplasia (AN), although this only includes 
participants with a positive result at the next screening round and not those 
who had a negative test result at the subsequent round. CRC screening 
programmes using FIT have adopted a wide range of f-Hb cut-offs, and the 
Scottish Bowel Screening Programme FIT evaluation used a much higher f-
Hb cut-off than that used in most other countries. Our data allows some 
comparison of other strategies using lower f-Hb cut-offs. Combining the data 
presented here with that in our recent publication on IC arising in the cohort 
participating in the pilot evaluation of screening using FIT,1 if Scotland used a 
> 60.0 µg Hb/g faeces cut-off rather than the > 80.0 µg Hb/g faeces used in 
the FIT evaluation,4 then 25.6% additional colonoscopy would yield 20.0% 
more CRC, or at least possible pre-cursor lesions, presuming these were 
present at the time of the FIT-based screening. However, in addition to the 
reduction in the number of false negative screening test results, the number of 
false positive results will also increase, requiring assessment of the 
associated harms such as over-diagnosis of lesions that would never have 
become symptomatic and the risk of complications of colonoscopy. 
Further analysis was performed on clinical outcomes at the subsequent 
screening round of those with an initial f-Hb below the commonly used cut-off 
f-Hb > 20 µg Hb/g faeces.  With the prevalence of AN higher in those with f-
Hb between 1.0 and 19.9 µg Hb/g faeces than in those with undetectable f-
Hb, evidence is provided that f-Hb is a predictor of future risk of colorectal 
neoplasia, even at a lower f-Hb cut-off than that used in Scotland. 
It is well accepted that men have higher median f-Hb than women.9,10  
Therefore, it is surprising that the median initial f-Hb of participants with a 
positive screening test result at the next round was higher in women than in 
men, although this did not reach statistical significance.  Significantly higher 
median initial f-Hb was detected in women compared with men in those with 
non-neoplastic pathology or normal findings at colonoscopy triggered by a 
positive screening test result at the next screening round.  It appears from this 
analysis that men who had a false positive screening test result were more 
likely to have had a low f-Hb in the previous screening round before 
experiencing short term colonic blood loss to trigger their subsequent positive 
screening test result.  Women, however, may have had longer term colonic 
bleeding, rising over time.  The reasons for this are unclear and may be 
worthy of further study.  Although not statistically significant, median f-Hb of 
participants with CRC detected at the next screening round was higher in men 
than in women, but the opposite was apparent for HRA. In fact, previous 
median f-Hb for women with CRC was very similar to previous median f-Hb of 
men with HRA.  This further demonstrates the variation in f-Hb by gender as 
documented previously,9,10  which should be taken into account in setting cut-
off f-Hb to be used in any screening programme. 
An obvious weakness of this analysis is that different tests were employed in 
the two rounds screening examined. However, the cut-off employed in the 
quantitative FIT pilot evaluation was equivalent in terms of positivity to the 
current gFOBT/FIT algorithm to which the programme reverted. Of course, it 
would be of interest to conduct a similar study in which quantitative FIT was 
used in consecutive screening rounds to allow investigation of the variation in 
f-Hb over time according to diagnostic outcomes.   In addition, the number of 
CRC cases is low, limiting detailed analysis by sub-groups such as age, 
gender and lesion site. 
Two very recent studies comparing clinical outcomes between two 
consecutive screening rounds have emerged with very large cohorts allowing 
sub-analyses by gender and lesion site. Recent work from Spain showed that 
the second screening round was associated with lower median f-Hb and an 
increased proportion of proximal CRC.11 The authors suggested various 
strategies to improve diagnosis of proximal CRC, such as using a lower cut-
off f-Hb at the first compared with the second round. Another study from 
France has demonstrated that subsequent screening was associated with 
increased detection of proximal AN, particularly in women, and CRC was 
more often later stage.12 Here, it was concluded that, since  the late stage 
CRC were likely to be previously missed lesions, the findings stressed the 
importance of repeated screening after a previous negative test result. These 
studies demonstrate the scope that exists for further work into the relationship 
between f-Hb and outcomes in subsequent screening rounds according to 
various sub-groups, if working with a large enough sample size. 
Our data could impact on CRC screening strategies. Risk scoring models are 
becoming increasingly developed, with an escalation in published studies in 
recent years.13-22 We have confirmed that f-Hb does predict the presence of 
colorectal disease through analysis of positivity in the next screening round. In 
consequence, screening programmes using FIT and looking to apply risk-
scoring should certainly incorporate f-Hb into such models, along with age 
and gender, and perhaps deprivation,23 to improve their predictive power.  
The fact that f-Hb is related, not only to colorectal disease severity,24 but also 
to future risk, has important implications for FIT-based CRC screening 
strategies.   
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